AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6432119
Drug: Diuretic (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic (25 mg chlorthalidone)
Trial: 6432119
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta blocker (200 mg metoprolol)
Trial: 6432119
Drug: Combined agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined agent (chlorthalidone + metoprolol)
Trial: 29637714
Drug: C1 esterase
RxNorm normalized name: C1 esterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 esterase inhibitor (C1INH) 50 U/kg
Trial: 27554088
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 200 mg intravenous ibuprofen
Trial: 27554088
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 400 mg intravenous ibuprofen
Trial: 27554088
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 800 mg intravenous ibuprofen
Trial: 27554088
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 400 mg intravenous ibuprofen (four times per day)
Trial: 20089547
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no changes in drug therapy)
Trial: 18652103
Drug: Ephedrine IV
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine IV (10 mg)
Trial: 10486792
Drug: Continuous CEE
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous CEE medication (0.625 mg daily) with cyclical supplementation of 5 mg/day of medrogestone acetate for 24 weeks
Trial: 8942409
Drug: High-selenium group
RxNorm normalized name: HIGH SELENIUM YEAST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-selenium group (n = 7) received selenate-fortified formulas (0.36 mumol Se/L for preterm, 0.22 mumol Se/L for full-term)
Trial: 8942409
Drug: Low-selenium group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-selenium group (n = 10) received non-selenium-fortified formulas (0.12 mumol Se/L for preterm, 0.11 mumol Se/L for full-term)
Trial: 26965712
Drug: Oral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplementation enriched with EPA, arginine, and nucleotides before the operation (group IN)
Trial: 11792923
Drug: Nimodipine 30
RxNorm normalized name: nimodipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 30 mg twice daily for 3 weeks
Trial: 11792923
Drug: Nimodipine and
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine and Placebo (regardless of initial treatment)
Trial: 7554973
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive containing ethinylestradiol and gestodene (EE/GSD)
Trial: 7554973
Drug: Monophasic formulation
RxNorm normalized name: Monobasic Potassium Phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic formulation containing 35 micrograms ethinylestradiol and 250 micrograms norgestimate (EE/NGM)
Trial: 17190936
Drug: Estradiol gel
RxNorm normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol gel
Trial: 27717999
Drug: Dabigatran EM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran EM with bosutinib (100 mg)
Trial: 25073669
Drug: 750 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/day of biphenyl dimethyl dicarboxylate (DDB)
Trial: 25073669
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day of ursodeoxycholic acid (UDCA)
Trial: 22186979
Drug: HZT-501 (ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HZT-501 (ibuprofen 800 mg + double-dose famotidine)
Trial: 22186979
Drug: Ibuprofen alone
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen alone (800 mg)
Trial: 16860964
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1-3
Trial: 16860964
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group information based on British Medical Journal 'Best Treatments'
Trial: 12534408
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lansoprazole (n = 26)
Trial: 12534408
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg pantoprazole (n = 24)
Trial: 10650302
Drug: Estrogen/progestin replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen/progestin replacement therapy
Trial: 9023640
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg and amoxycillin 1000 mg twice daily for 14 days
Trial: 9023640
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg and placebo twice daily for 14 days
Trial: 25566817
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 or 50 mg for 6 months)
Trial: 24059992
Drug: TwHF (1‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TwHF (1‐2 mg·kg⁻¹·d⁻¹)
Trial: 24059992
Drug: Irbesartan (150‐300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (150‐300 mg/d)
Trial: 24059992
Drug: TwHF combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TwHF combined with irbesartan (TwHF 1‐2 mg·kg⁻¹·d⁻¹ + irbesartan 150‐300 mg/d)
Trial: 21716965
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of implants following the Columbus Bridge Protocol (4 to 6 implants loaded within 24 hours)
Trial: 21716965
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading of implants following the ad modum Branemark protocol (6 to 9 implants loaded a mean 8.75 months after surgery)
Trial: 16446006
Drug: Prototype formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype formulation of metoprolol succinate
Trial: 16446006
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation Beloc-zok
Trial: 11447769
Drug: Intravenous 2
RxNorm normalized name: Premarin Intravenous 25 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 2 mg tropisetron (single injection)
Trial: 11447769
Drug: Intravenous 2
RxNorm normalized name: Premarin Intravenous 25 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 2 mg tropisetron (daily for 5 days)
Trial: 11447769
Drug: Peroral daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroral daily treatment with 5 mg tropisetron
Trial: 9625105
Drug: 8.7 mg
RxNorm normalized name: menthol 8.7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.7 mg every 2 weeks (group A)
Trial: 9625105
Drug: 29.7 mg
RxNorm normalized name: vitamin C 75 MG / ferrous fumarate 90 MG (iron 29.7 MG) Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 29.7 mg every month (group B)
Trial: 9625105
Drug: 148.2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 148.2 mg every 3 months (group C)
Trial: 9625105
Drug: 382 mg
RxNorm normalized name: carbenicillin 382 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 382 mg every 6 months (group D)
Trial: 9625105
Drug: 993 mg
RxNorm normalized name: OCTINOXATE 2449 mg in 30 mL / OCTOCRYLENE 993 mg in 30 mL / TITANIUM DIOXIDE 1522 mg in 30 mL TOPICAL CREAM [CLE DE PEAU BEAUTE UV PROTECTIVE TINTED DARK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 993 mg once (group E)
Trial: 3045295
Drug: Captopril (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (6 mg orally)
Trial: 3045295
Drug: Saralasin acetate
RxNorm normalized name: saralasin acetate
DrugBank: Saralasin (DB06763)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saralasin acetate (50 ng kg‐1 min‐1 intravenous infusion)
Trial: 15333400
Drug: Ropivacaine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 20 mg
Trial: 29236228
Drug: Ropivacaine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 25 mg
Trial: 23719546
Drug: N-acetylcysteine (NAC;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC; 20 mg · kg(‐1) · d(‐1))
Trial: 18258715
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (NAC) with paclitaxel plus carboplatin followed by interval debulking surgery and an additional four cycles of postsurgical chemotherapy
Trial: 18258715
Drug: Primary debulking
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary debulking surgery (PDS) followed by eight cycles of postsurgical chemotherapy with or without interval debulking surgery
Trial: 16466688
Drug: Videoconferencing-based cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videoconferencing-based cognitive-behavioral therapy (CBT)
Trial: 14587411
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of contrast material (Iomeprol 300 mgI/ml or 350 mgI/ml) only
Trial: 14587411
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of contrast material (300 mgI/ml or 350 mgI/ml) flushed with 50 ml of saline solution at a rate of 5 ml/sec
Trial: 12141525
Drug: Surfactant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant treatment in infants with RDS
Trial: 3324526
Drug: Verapamil (mean,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (mean, 493 +/- 136 mg/day)
Trial: 3324526
Drug: Propranolol (mean,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (mean, 340 +/- 135 mg/day)
Trial: 31726490
Drug: Intrapleural infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrapleural infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight
Trial: 31726490
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight
Trial: 27860499
Drug: Insulin LM75/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin LM75/25
Trial: 11818027
Drug: Intraoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiation therapy (IORT) with a dose of 12-15 Gy (median 15 Gy) followed by postoperative external radiation therapy (EXRT) with a median total dose of 60 Gy.
Trial: 11818027
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with postoperative external radiation therapy (EXRT) alone.
Trial: 2376428
Drug: Dextromethorphan-salbutamol combination
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan-salbutamol combination tablet (Redol comp)
Trial: 2376428
Drug: Plain dextromethorphan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain dextromethorphan tablet (Extuson)
Trial: 14503
Drug: Acebutolol (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (2.0 g total dosage over 48 hours)
Trial: 31997647
Drug: Adapted alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted alternating treatments design
Trial: 31997647
Drug: Alternative methods
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative methods (e.g., random assignment)
Trial: 24843631
Drug: Exenatide once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide once-weekly (EQW)
Trial: 21752951
Drug: 1/5 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/5 dose of Meningococcal ACWY polysaccharide (PsACWY)
Trial: 19710585
Drug: School-based sore
RxNorm normalized name: Sucrets Sore Throat
DrugBank: Dyclonine (DB00645)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: School-based sore throat clinic program with free nurse-observed oral penicillin treatment of group A streptococcal pharyngitis
Trial: 12890841
Drug: High-dose bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bevacizumab (10 mg/kg every two weeks)
Trial: 12890841
Drug: Low-dose bevacizumab
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose bevacizumab (3 mg/kg every two weeks)
Trial: 10199350
Drug: Spinal-cord stimulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal-cord stimulation in addition to best medical treatment
Trial: 7766296
Drug: Low-dose OKT3
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose OKT3 (0.5 mg twice daily)
Trial: 7766296
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose OKT3 (5 mg daily)
Trial: 2279744
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide using 0.025% cream
Trial: 7437907
Drug: Pizotifen 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifen 2 mg (single oral dose)
Trial: 7437907
Drug: Methysergide (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methysergide (dosage not specified)
Trial: 7437907
Drug: Bromocriptine 2.5
RxNorm normalized name: bromocriptine 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 2.5 mg twice daily for 4 days
Trial: 7437907
Drug: Pizotifen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pizotifen 0.5 mg 3 times daily for 12 days
Trial: 28641315
Drug: Sequential regimen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen: 4 cycles of epirubicin 90 mg/m² followed by 4 cycles of docetaxel 75 mg/m²
Trial: 28641315
Drug: Concurrent regimen:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent regimen: 6 cycles of epirubicin 75 mg/m² plus docetaxel 75 mg/m²
Trial: 24617000
Drug: SIT (standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIT (standardized allergen vaccine)
Trial: 16565866
Drug: Supplemental nocturnal
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Supplemental nocturnal oxygen (3 l/min) (n = 16)
Trial: 14601199
Drug: 2.5 ml
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 ml 0.75% ropivacaine (18.75 mg)
Trial: 14601199
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml 0.75% ropivacaine (22.5 mg)
Trial: 10991865
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of racemic dOTC
Trial: 10991865
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of racemic dOTC
Trial: 10991865
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of racemic dOTC
Trial: 10991865
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg of racemic dOTC
Trial: 10991865
Drug: 1600 mg
RxNorm normalized name: glycerin 1600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1600 mg of racemic dOTC
Trial: 8854777
Drug: Continuous hepatic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hepatic artery infusion of 5-FU (500 mg x 4 days/week for six weeks from 2 weeks after surgery)
Trial: 8854777
Drug: Oral 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral 5-FU from 2 weeks after surgery
Trial: 1296454
Drug: IL-2 at
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 at a dose of 3 million IU subcutaneously twice/daily for 6 days/week for 4 weeks
Trial: 1296454
Drug: IL-2 once/daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 once/daily in the evening
Trial: 1296454
Drug: IL-2 once/daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 once/daily plus MLT at 10 or at 50 mg/day
Trial: 1296454
Drug: IL-2 given
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 given twice/daily
Trial: 6084924
Drug: Desogestrel (0.150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel (0.150 mg) plus Ethinyl Estradiol (0.03 mg)
Trial: 6084924
Drug: Levonorgestrel (0.150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel (0.150 mg) plus Ethinyl Estradiol (0.03 mg)
Trial: 26655493
Drug: Low-dose fentanyl
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fentanyl (1 μg/kg)
Trial: 26655493
Drug: High-dose fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fentanyl (10 μg/kg)
Trial: 24371300
Drug: Oral antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidant therapy (mixed tocopherols 666 IU/d plus α-lipoic acid 600 mg/d)
Trial: 22770692
Drug: High thoracic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High thoracic epidural analgesia (HTEA) as a supplement to general anesthesia
Trial: 17940111
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone patches
Trial: 12792707
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg orally every 8 h)
Trial: 12792707
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg on the first day, 100 mg/day thereafter)
Trial: 12792707
Drug: Captopril-Aspirin (Captopril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril-Aspirin (Captopril on the first day, followed by Aspirin)
Trial: 12792707
Drug: Aspirin-Captopril (Aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin-Captopril (Aspirin on the first day, followed by Captopril)
Trial: 17182183
Drug: Nortriptyline (25-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (25-100 mg)
Trial: 1694647
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulphate (20 mg elemental zinc twice daily)
Trial: 15279521
Drug: Reduction counseling
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction counseling plus nicotine replacement therapy (NRT) plus brief advice to quit
Trial: 11595291
Drug: Cytokines administration
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytokines administration with or without therapeutic vaccination in HAART treated patients
Trial: 11595291
Drug: Treatment interruption
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment interruption (TI) or drug therapy change from a PI- to a non-nucleoside-based HAART regimen
Trial: 11595291
Drug: HAART (Protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART (Protease inhibitor-based)
Trial: 9625829
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (lobectomy, sleeve lobectomy, bilobectomy)
Trial: 3278876
Drug: 150 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 micrograms levothyroxine (T4) daily (group I, n = 35)
Trial: 3278876
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms levothyroxine and 130.8 micrograms potassium iodide daily (group II, n = 39)
Trial: 3278876
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms iodide daily (prophylactic administration after initial treatment)
Trial: 29385323
Drug: LY3016859 (LY)
RxNorm normalized name: LYS
DrugBank: Fepixnebart (DB19079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3016859 (LY) administered intravenously (0.1-750 mg) or subcutaneously (50 mg)
Trial: 29385323
Drug: LY3016859 (LY)
RxNorm normalized name: LYS
DrugBank: Fepixnebart (DB19079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3016859 (LY) administered intravenously (10-750 mg)
Trial: 29385323
Drug: LY3016859 (LY)
RxNorm normalized name: LYS
DrugBank: Fepixnebart (DB19079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3016859 (LY) administered intravenously (50-750 mg)
Trial: 27721247
Drug: Oxycodone 1
RxNorm normalized name: oxycodone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 1 mg/kg plus tropisetron 0.1 mg/kg for PCIA
Trial: 27721247
Drug: Dezocine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dezocine 0.6 mg/kg plus tropisetron 0.1 mg/kg for PCIA
Trial: 27721247
Drug: Oxycodone group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone group